Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer

Lung Cancer

Volumn 59, Issue 2, 2008, Pages 240-245

  Derin, Duygu ^a   Soydinç, Hilal Oguz ^a   Guney, Nese ^a   Tas, Faruk ^a   Çamlica, Hakan ^a   Duranyildiz, Derya ^a   Yasasever, Vildan ^a   Topuz, Erkan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Nonsmall cell lung cancer; Survivin; TNF alpha

Indexed keywords

BIOLOGICAL MARKER; PLATINUM DERIVATIVE; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; AGED; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PLATINUM COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38649092679     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.08.005     Document Type: Article

References (39)

1. Belani C.P., and Langer C. First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer 38 Suppl 4 (2002) 13-19
2. Gridelli C., Rossi A., and Maione P. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene 22 (2003) 6629-6638
3. Cross M., and Dexter T.M. Growth factors in development, transformation and tumorigenesis. Cell 64 (1991) 271-280
4. Kerr J.F., Winterford C.M., and Harmon B.V. Apoptosis: its significance in cancer and cancer therapy. Cancer 73 (1994) 2013-2026
5. Raff M. Cell suicide for beginners. Nature 396 (1998) 119-122
6. Reed J.C. The survivin saga goes in vivo. J Clin Invest 108 (2001) 965-969
7. LaCasse E.C., Baird S., Komeluk R.G., and Mackenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17 (1998) 3247-3259
8. Altieri D.C. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7 (2001) 542-547
9. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
10. Tanaka K., Iwamoto S., Gon G., Nohara T., Iwamoto M., and Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6 (2000) 127-134
11. Kawasaki H., Altieri D.C., Lu C.D., Toyoda M., Tenjo T., and Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58 (1998) 5071-5074
12. Tamm I., Wang Y., Sausville E., Scudiero D.A., Vigna N., Oltersdorf T., et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by FAS (CD95), Bax, caspases and anticancer drugs. Cancer Res 58 (1998) 5315-5320
13. Lu C.D., Altieri D.C., and Tanigawa N. Expression of a novel apoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58 (1998) 1808-1812
14. Kato J., Kuwabara Y., Mitani M., Shinoda N., Sato A., Toyama T., et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95 (2001) 92-95
15. Takai N., Miyazaki T., Nishida M., Nasu K., and Miyakawa I. Survivin expression correlates with clinical stages, histologic grade, invasive behavior and survival rates in endometrial carcinoma. Cancer Lett 184 (2002) 105-116
16. Zaffaroni N., Pennati M., Colella G., Perego P., Supino R., Gatti L., et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 59 (2002) 1406-1412
17. Monzo M., Rosell R., Felip E., Astudillo J., Sanchez J.J., Maestre J., et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancer. J Clin Oncol 17 (1999) 2100-2104
18. Hofmann H.S., Simm A., Hammer A., Silber R.E., and Bartling B. Expression of inhibitors of apoptosis(IAP) proteins in non-small-cell human lung cancer. J Cancer Res Clin Oncol 128 (2002) 554-560
19. Ikehara M., Oshita F., Kameda Y., Ito H., Ohgane N., Suzuki R., et al. Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small cell adenocarcinoma of the lung. Oncol Rep 9 (2002) 835-838
20. Sidoti-De Fraisse C., Rincheval V., Risler Y., Mignotte B., and Vayssiere J.L. TNF-α activates at least two apoptotic signaling cascades. Oncogene 17 (1998) 1639-1651
21. Schiller J.H., and Bittner G. Anti-proliferative effects of tumor necrosis factor, gamma interferon and 5-fluorouracil on human colorectal carcinoma cell lines. Int J Cancer 46 (1990) 61-66
22. Kemeny N., Childs B., Larchian W., Rosado K., and Kelsen D. A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer 66 (1990) 659-663
23. Skillings J., Wierzbicki R., Eisenhauer E., Venner P., Letendre F., Stewart D., et al. A phase II study of recombinant tumor necrosis factor alpha in renal cell carcinoma: a study of the National Cancer Institute of Canada Clinical Trial Group. J Immunother 11 (1992) 67-70
24. Lienard D., Lejeune F.J., and Ewalenko P. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 16 (1992) 234-240
25. Hong W.S., Jett J.R., Sasaki Y., Takahashi H., Nakano H., Nakagawa K., et al. Colony inhibitory effect of recombinant human interferon(rH-IFN)-alpha-beta and -gamma on human lung cancer cell lines. Jpn J Clin Oncol 17 (1987) 49-55
26. Yang S.C., Owen-Schaub L.B., Grimm E.A., and Roth J.A. Induction of lymphokines-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets. Cancer Immunol Immunother 29 (1989) 193-198
27. Boldrini L., Gisfredi S., Ursi{dotless}no S., Lucchi M., Melfi F., Mussi A., et al. Tumor necrosis factor-alpha: prognostic role and relationship with interleukin-8 and endothelin-1 in non-small cell lung cancer. Int J Mol Med 17 (2006) 887-892
28. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
29. Tanabe H., Yagihashi A., Tsuji N., Shijubo Y., Abes S., and Watanabe N. Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. Lung Cancer 46 (2004) 299-304
30. Falleni M., Pellegrini C., Marchetti A., Oprandi B., Buttitta F., Barassi F., et al. Survivin gene expression in early non-small cell lung cancer. J Pathol 200 (2003) 620-626
31. Vischioni B., van der Valk P., Span S.W., Kruyt F.A., Rodriguez J.A., and Giaccone G. Nuclear localization of survivin is a positive prognostic factor for survival in advanced NSCLC. Ann Oncol 15 (2004) 1654-1660
32. Karczmarek-Borowska B., Filip A., Wojcierowski J., Smolen A., Pilecka I., and Jablonka A. Survivin antiapoptotic gene expression as a prognostic factor in non-small cell lung cancer: in situ hbridization study. Folia Histochem Cytobiol 43 (2005) 237-242
33. Kren L., Brazdil J., Hermanova M., Goncharuk V.N., Kallakury B.V., Kaur P., et al. Prognostic significance of anti-apoptotisis proteins survivin and bcl-2 in non-small cell lung carcinoma: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol 12 (2004) 44-49
34. Kaminska J., Kowalska M., Kotowicz B., Fuksiewicz M., Glogowski M., Wojcik E., et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF-an independent prognostic factor. Oncology 70 (2006) 115-125
35. Tas F., Duranyi{dotless}ldi{dotless}z D., Argon A., Oguz H., Camlica H., Yasasever V., et al. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol 22 (2005) 353-358
36. Kayacan O., Karnak D., Beder S., Gullu E., Tutkak H., Senler F.C., et al. Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients. Am J Clin Oncol 29 (2006) 328-335
37. De Vita F., Orditura M., Auriemma A., Infusino S., and Catalano G. Serum concentrations of proinflammatory cytokines in advanced non small cell lung cancer patients. J Exp Clin Cancer Res 17 (1998) 413-417
38. Niiya M., Niiya K., Kiguchi T., Shibakura M., Asaumi N., Shinagawa K., et al. Induction of TNF-alpha, Upa. IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells. Cancer Chemother Pharmacol 52 (2003) 391-398
39. O'Brien M.E., Saini A., Smith I.E., Webb A., Gregory K., Mendes R., et al. A randomized phase II study of SRL172 combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 83 (2000) 853-857